Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation

Molecular Oncology

Volumn 9, Issue 7, 2015, Pages 1392-1405

  Reyes Reyes, E Merit ^a,b,c   Šalipur, Francesca R ^b   Shams, Mitra ^b   Forsthoefel, Matthew K ^b   Bates, Paula J ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Aptamer; AS1411; Macropinocytosis; Methuosis; Nucleolin; Rac1

Indexed keywords

APTAMER; AS 1411; EPIDERMAL GROWTH FACTOR RECEPTOR; NUCLEOLIN; PROTEIN KINASE B; RAC1 PROTEIN; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; AGRO 100; MITOGEN ACTIVATED PROTEIN KINASE P38; OLIGODEOXYRIBONUCLEOTIDE; PHOSPHOPROTEIN; RNA BINDING PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CELL DEATH; CELL VACUOLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; METASTASIS; PINOCYTOSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; ANIMAL; CELL LINE; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; METABOLISM; PHYSIOLOGY;

ANIMALS; APTAMERS, NUCLEOTIDE; CELL LINE; CELL PROLIFERATION; HUMANS; OLIGODEOXYRIBONUCLEOTIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOPROTEINS; PINOCYTOSIS; RAC1 GTP-BINDING PROTEIN; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA-BINDING PROTEINS;

EID: 84938216208     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.03.012     Document Type: Article

References (51)

1. Abdelmohsen K., Gorospe M. RNA-binding protein nucleolin in disease. RNA Biol. 2012, 9:799-808.
2. Abdelmohsen K., Tominaga K., Lee E.K., Srikantan S., Kang M.J., Kim M.M., Selimyan R., Martindale J.L., Yang X., Carrier F., Zhan M., Becker K.G., Gorospe M. Enhanced translation by nucleolin via G-rich elements in coding and non-coding regions of target mRNAs. Nucleic Acids Res. 2011, 39:8513-8530.
3. Anton I.M., Saville S.P., Byrne M.J., Curcio C., Ramesh N., Hartwig J.H., Geha R.S. WIP participates in actin reorganization and ruffle formation induced by PDGF. J. Cell Sci. 2003, 116:2443-2451.
4. Bates P.J., Choi E.W., Nayak L.V. G-rich oligonucleotides for cancer treatment. Methods Mol. Biol. 2009, 542:379-392.
5. Bates P.J., Kahlon J.B., Thomas S.D., Trent J.O., Miller D.M. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J. Biol. Chem. 1999, 274:26369-26377.
6. Bates P.J., Laber D.A., Miller D.M., Thomas S.D., Trent J.O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol. 2009, 86:151-164.
7. Bhanot H., Young A.M., Overmeyer J.H., Maltese W.A. Induction of nonapoptotic cell death by activated Ras requires inverse regulation of Rac1 and Arf6. Mol. Cancer Res. 2010, 8:1358-1374.
8. Bid H.K., Roberts R.D., Manchanda P.K., Houghton P.J. RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis. Mol. Cancer Ther. 2013, 12:1925-1934.
9. Birchenall-Roberts M.C., Fu T., Kim S.G., Huang Y.K., Dambach M., Resau J.H., Ruscetti F.W. K-Ras4B proteins are expressed in the nucleolus: interaction with nucleolin. Biochem. Biophys. Res. Commun. 2006, 348:540-549.
10. Borer R.A., Lehner C.F., Eppenberger H.M., Nigg E.A. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989, 56:379-390.
11. Bou-Assaly W., Mukherji S. Cetuximab (erbitux). AJNR. Am. J. Neuroradiol 2010, 31:626-627.
12. Commisso C., Davidson S.M., Soydaner-Azeloglu R.G., Parker S.J., Kamphorst J.J., Hackett S., Grabocka E., Nofal M., Drebin J.A., Thompson C.B., Rabinowitz J.D., Metallo C.M., Vander Heiden M.G., Bar-Sagi D. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013, 497:633-637.
13. Dam D.H., Culver K.S., Odom T.W. Grafting aptamers onto gold nanostars increases in vitro efficacy in a wide range of cancer cell types. Mol. Pharmaceutics 2014, 11:580-587.
14. Daniely Y., Borowiec J.A. Formation of a complex between nucleolin and replication protein A after cell stress prevents initiation of DNA replication. J. Cell Biol. 2000, 149:799-810.
15. Douglas M.R., Morrison K.C., Jacques S.J., Leadbeater W.E., Gonzalez A.M., Berry M., Logan A., Ahmed Z. Off-target effects of epidermal growth factor receptor antagonists mediate retinal ganglion cell disinhibited axon growth. Brain 2009, 132:3102-3121.
16. Dowrick P., Kenworthy P., McCann B., Warn R. Circular ruffle formation and closure lead to macropinocytosis in hepatocyte growth factor/scatter factor-treated cells. Eur. J. Cell Biol. 1993, 61:44-53.
17. Farin K., Di Segni A., Mor A., Pinkas-Kramarski R. Structure-function analysis of nucleolin and ErbB receptors interactions. PloS One 2009, 4:e6128.
18. Farin K., Schokoroy S., Haklai R., Cohen-Or I., Elad-Sfadia G., Reyes-Reyes M.E., Bates P.J., Cox A.D., Kloog Y., Pinkas-Kramarski R. Oncogenic synergism between ErbB1, nucleolin, and mutant Ras. Cancer Res. 2011, 71:2140-2151.
19. Girvan A.C., Teng Y., Casson L.K., Thomas S.D., Juliger S., Ball M.W., Klein J.B., Pierce W.M., Barve S.S., Bates P.J. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol. Cancer Ther. 2006, 5:1790-1799.
20. Goldshmit Y., Trangle S.S., Kloog Y., Pinkas-Kramarski R. Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma. Oncotarget 2014, 5:8602-8613.
21. Haeusler A.R., Donnelly C.J., Periz G., Simko E.A., Shaw P.G., Kim M.S., Maragakis N.J., Troncoso J.C., Pandey A., Sattler R., Rothstein J.D., Wang J. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature 2014, 507:195-200.
22. Haigler H.T., McKanna J.A., Cohen S. Rapid stimulation of pinocytosis in human carcinoma cells A-431 by epidermal growth factor. J. Cell Biol. 1979, 83:82-90.
23. Hovanessian A.G., Soundaramourty C., El Khoury D., Nondier I., Svab J., Krust B. Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PloS One 2010, 5:e15787.
24. Hyatt D.C., Ceresa B.P. Cellular localization of the activated EGFR determines its effect on cell growth in MDA-MB-468 cells. Exp. Cell Res. 2008, 314:3415-3425.
25. Inder K.L., Hill M.M., Hancock J.F. Nucleophosmin and nucleolin regulate K-Ras signaling. Communicative Integr. Biol. 2010, 3:188-190.
26. Inder K.L., Lau C., Loo D., Chaudhary N., Goodall A., Martin S., Jones A., van der Hoeven D., Parton R.G., Hill M.M., Hancock J.F. Nucleophosmin and nucleolin regulate K-Ras plasma membrane interactions and MAPK signal transduction. J. Biol. Chem. 2009, 284:28410-28419.
27. Kitambi S.S., Toledo E.M., Usoskin D., Wee S., Harisankar A., Svensson R., Sigmundsson K., Kalderen C., Niklasson M., Kundu S., Aranda S., Westermark B., Uhrbom L., Andang M., Damberg P., Nelander S., Arenas E., Artursson P., Walfridsson J., Forsberg Nilsson K., Hammarstrom L.G., Ernfors P. Vulnerability of glioblastoma cells to catastrophic vacuolization and death induced by a small molecule. Cell 2014, 157:313-328.
28. Kundu S.T., Nallur S., Paranjape T., Boeke M., Weidhaas J.B., Slack F.J. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel. Cell Cycle 2012, 11:361-366.
29. Laber D.A., Bates P.J., Trent J.O., Barnhart K., Taft B., Miller D.M. Long term clinical response in renal cell carcinoma patients treated with quadruplex forming oligonucleotides. Clin. Cancer Res. 2005, 11:9088S.
30. Li C., Macdonald J.I., Hryciw T., Meakin S.O. Nerve growth factor activation of the TrkA receptor induces cell death, by macropinocytosis, in medulloblastoma Daoy cells. J. Neurochem. 2010, 112:882-899.
31. Lim J.P., Gleeson P.A. Macropinocytosis: an endocytic pathway for internalising large gulps. Immunol. Cell Biol. 2011, 89:836-843.
32. Maltese W.A., Overmeyer J.H. Methuosis: nonapoptotic cell death associated with vacuolization of macropinosome and endosome compartments. Am. J. Pathol. 2014, 184:1630-1642.
33. Mercer J., Helenius A. Virus entry by macropinocytosis. Nat. Cell Biol. 2009, 11:510-520.
34. Miyata Y., Hoshi M., Koyasu S., Kadowaki T., Kasuga M., Yahara I., Nishida E., Sakai H. Rapid stimulation of fluid-phase endocytosis and exocytosis by insulin, insulin-like growth factor-I, and epidermal growth factor in KB cells. Exp. Cell Res. 1988, 178:73-83.
35. Mooren O.L., Galletta B.J., Cooper J.A. Roles for actin assembly in endocytosis. Annu. Rev. Biochem. 2012, 81:661-686.
36. Nara A., Aki T., Funakoshi T., Unuma K., Uemura K. Hyperstimulation of macropinocytosis leads to lysosomal dysfunction during exposure to methamphetamine in SH-SY5Y cells. Brain Res. 2012, 1466:1-14.
37. Overmeyer J.H., Kaul A., Johnson E.E., Maltese W.A. Active ras triggers death in glioblastoma cells through hyperstimulation of macropinocytosis. Mol. Cancer Res. 2008, 6:965-977.
38. Overmeyer J.H., Maltese W.A. Death pathways triggered by activated Ras in cancer cells. Front. Biosci. 2011, 16:1693-1713.
39. Pan H., Yu J., Zhang L., Carpenter A., Zhu H., Li L., Ma D., Yuan J. A novel small molecule regulator of guanine nucleotide exchange activity of the ADP-ribosylation factor and golgi membrane trafficking. J. Biol. Chem. 2008, 283:31087-31096.
40. Pichiorri F., Palmieri D., De Luca L., Consiglio J., You J., Rocci A., Talabere T., Piovan C., Lagana A., Cascione L., Guan J., Gasparini P., Balatti V., Nuovo G., Coppola V., Hofmeister C.C., Marcucci G., Byrd J.C., Volinia S., Shapiro C.L., Freitas M.A., Croce C.M. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J. Exp. Med. 2013, 210:951-968.
41. Reyes-Reyes E.M., Teng Y., Bates P.J. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 2010, 70:8617-8629.
42. Ridley A.J., Paterson H.F., Johnston C.L., Diekmann D., Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992, 70:401-410.
43. Rizzieri D., Stockerl-Goldstein K., Wei A., Herzig R.H., Erlandsson F., S R.K. Long term outcomes of responders in a randomized, controlled Phase II trial of aptamer AS1411 in AML. J. Clin. Oncol. 2010, 28:15S.
44. Robinson M.W., Overmeyer J.H., Young A.M., Erhardt P.W., Maltese W.A. Synthesis and evaluation of indole-based chalcones as inducers of methuosis, a novel type of nonapoptotic cell death. J. Med. Chem. 2012, 55:1940-1956.
45. Rosenberg J.E., Bambury R.M., Van Allen E.M., Drabkin H.A., Lara P.N., Harzstark A.L., Wagle N., Figlin R.A., Smith G.W., Garraway L.A., Choueiri T., Erlandsson F., Laber D.A. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest. New Drugs 2013, 32:178-187.
46. Rush J.S., Quinalty L.M., Engelman L., Sherry D.M., Ceresa B.P. Endosomal accumulation of the activated epidermal growth factor receptor (EGFR) induces apoptosis. J. Biol. Chem. 2012, 287:712-722.
47. Semenkovich C.F., Ostlund R.E., Olson M.O., Yang J.W. A protein partially expressed on the surface of HepG2 cells that binds lipoproteins specifically is nucleolin. Biochemistry 1990, 29:9708-9713.
48. Shen N., Yan F., Pang J., Wu L.C., Al-Kali A., Litzow M.R., Liu S. A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis. Oncotarget 2014, 5:5494-5509.
49. Shieh Y.A., Yang S.J., Wei M.F., Shieh M.J. Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano 2010, 4:1433-1442.
50. Soundararajan S., Chen W., Spicer E.K., Courtenay-Luck N., Fernandes D.J. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 2008, 68:2358-2365.
51. Teng Y., Girvan A.C., Casson L.K., Pierce W.M., Qian M., Thomas S.D., Bates P.J. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res. 2007, 67:10491-10500.